FHIRsmith: FHIR Resources

FHIR IG analytics

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | pt | se | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds

270,995 resources (JSON | CSV)

Type:
Text: Package: Only Show Used

By Version

R2: 117
R2B: 0
R3: 21,787
R4: 158,444
R4B: 43,719
R5: 32,499
R6: 2,222

By Authority

none: 189,580
hl7: 74,857
ihe: 1,324
national: 3,888
who: 1,346

By Realm

none: 183,568
au: 736
be: 606
br: 400
ca: 1,464
ch: 1,776
cl: 564
cr: 117
cz: 862
de: 2,090
dk: 1,497
ee: 260
eu: 967
fi: 87
fr: 3,334
il: 328
in: 163
it: 116
jp: 174
kr: 30
nl: 2,247
no: 125
nz: 240
pl: 258
pt: 50
se: 161
stt: 116
tw: 1,414
uk: 6
us: 23,032
uv: 44,063
vn: 108
other: 6

Start Prev Rows 226400 - 226600 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth	Usage #
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.117.1.7.1.87.json	Discharge To Acute Care Facility	active	2021-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.117.1.7.1.93.json	Patient Refusal	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1434.1047.json	Skin Melanoma pT1	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.100.json	Injectable Fluorouracil	active	2020-09	us	hl7	3
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.101.json	Trastuzumab and Biosimilars	active	2023-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.102.json	Breast Cancer	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.103.json	HER2 Presence in Tissue	active	2020-09	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.104.json	Depression Screening for Adult	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.105.json	Long Acting Opioids	active	2024-08	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.106.json	High Fiber Supplement or Diet Education	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.107.json	Standardized Assessment Tools for Dyspnea	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.108.json	Nausea or Vomiting Assessment	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.109.json	Pancreatic Cancer	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.110.json	Pancreatic Cancer	active	2023-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.111.json	Audio Visual Telehealth Encounter	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.112.json	Telephone Encounter	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.113.json	Telehealth Emergency Department or Initial Inpatient	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.114.json	Karnofsky Performance Status	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.115.json	Referral to Hospice Care	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.116.json	Referral to Palliative Care	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.117.json	Assessment Scale for Dyspnea	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.118.json	Nausea or Vomiting Assessment	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.119.json	Enrollment in Hospice Care	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.120.json	Palliative Care	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.121.json	Advance Directive Including Durable Power of Attorney or Instructional	active	2020-10	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.122.json	Carmustine Injectable	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.123.json	Dacarbazine Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.124.json	Streptozocin Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.126.json	Alemtuzumab Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.127.json	Azacitidine Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.128.json	Bendamustine Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.129.json	Busulfan Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.130.json	Temozolomide Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.131.json	Thiotepa Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.132.json	Oxaliplatin Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.133.json	Romidepsin Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.134.json	Trabectedin Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.135.json	Dolasetron Oral	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.136.json	Dolasetron Injectable	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.137.json	Granisetron Oral	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.138.json	Granisetron Transdermal	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.139.json	Granisetron Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.140.json	Ondansetron Oral	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.141.json	Ondansetron Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.142.json	Ifosfamide Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.143.json	Arsenic Trioxide Injectable	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.144.json	Netupitant Palonosetron Oral	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.145.json	Fosnetupitant Palonosetron Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.146.json	Aprepitant Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.147.json	Rolapitant Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.148.json	Dexamethasone Oral	active	2022-09	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.149.json	Dexamethasone Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.150.json	Dexamethasone Drug Implant	active	2025-04	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.151.json	Olanzapine Oral	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.152.json	Olanzapine Injectable	active	2021-03	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.153.json	Idarubicin Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.154.json	Neurokinin 1 Receptor Antagonist Ingredient	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.155.json	Serotonin Receptor Antagonist Ingredient	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.156.json	Clofarabine Injectable	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.157.json	Belinostat Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.158.json	Bortezomib Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.159.json	Cabazitaxel Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.160.json	Carfilzomib Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.161.json	Decitabine Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.162.json	Elotuzumab Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.163.json	Enfortumab Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.164.json	Eribulin Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.165.json	Etoposide Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.166.json	Inotuzumab Ozogamicin Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.167.json	Mitoxantrone Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.168.json	Moxetumomab Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.169.json	Necitumumab Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.170.json	Nelarabine Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.171.json	Temsirolimus Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.172.json	Tisagenlecleucel Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.173.json	Topotecan Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.178.json	Atezolizumab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.179.json	Avelumab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.180.json	Bleomycin Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.181.json	Cemiplimab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.182.json	Cladribine Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.183.json	Daratumumab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.184.json	Durvalumab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.185.json	Emapalumab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.186.json	Fludarabine Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.187.json	Ipilimumab Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.188.json	Nivolumab Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.189.json	Pembrolizumab Injectable	active	2024-12	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.190.json	Polatuzumab Vedotin Injectable	active	2021-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.191.json	Pralatrexate Injectable	active	2021-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.192.json	Vincristine Injectable	active	2021-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.193.json	Methotrexate Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.194.json	Trastuzumab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.195.json	Mitomycin Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.196.json	Brentuximab Vedotin Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.197.json	Doxorubicin Pegylated Liposomal Injectable	active	2024-11	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.198.json	Blinatumomab Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.199.json	Trastuzumab Emtansine Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.200.json	Gemtuzumab Ozogamicin Injectable	active	2021-05	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.201.json	Tagraxofusp Injectable	active	2024-12	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.202.json	Axicabtagene Ciloleucel Injectable	active	2024-11	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.203.json	BRCA1	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.204.json	BRCA2	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.205.json	BRCA1 Testing	active	2023-06	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.207.json	Epithelial Ovarian Cancer	active	2024-08	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.208.json	Primary Peritoneal Cancer	active	2022-06	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.209.json	Fallopian Tube Cancer	active	2022-06	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.210.json	Multigene Panel	active	2023-07	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.211.json	BRCA1 and BRCA2	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.212.json	BRCA1 and BRCA2 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.213.json	BRAF V600	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.214.json	BRAF V600 Testing	active	2023-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.215.json	Colorectal Cancer	active	2024-08	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.216.json	BRAF V600 Mutation Status	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.217.json	Cancer Stage I	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.218.json	Head and Neck Cancer	active	2022-02	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.219.json	Malignant Melanoma of Skin	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.220.json	Brain Cancer	active	2022-07	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.221.json	Waldenstrom Macroglobulinemia	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.222.json	High Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.223.json	Moderate Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.224.json	Docetaxel Injectable	active	2024-12	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.225.json	Cyclophosphamide Injectable	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.226.json	LAG 3 Inhibitor	active	2024-11	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.233.json	Chemotherapy Administration	active	2024-01	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.240.json	Pathological N Stage N3c	active	2024-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.241.json	Audio Visual Telehealth Encounter	active	2025-01	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.242.json	Moderate or High Emetic Risk Oral Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.243.json	Minimal to Low Emetic Risk Oral Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.244.json	Copanlisib Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.245.json	Isatuximab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.246.json	Loncastuximab tesirine Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.247.json	Margetuximab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.248.json	Mirvetuximab soravtansine Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.249.json	Tafasitamab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.250.json	Teclistamab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.251.json	Tisotumab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.252.json	Asparaginase Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.254.json	Belantamab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.255.json	Dostarlimab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.256.json	Mosunetuzumab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.257.json	Tremelimumab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.258.json	Indication for Dexamethasone	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.260.json	Indication for Olanzapine	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.261.json	Indication for Dexamethasone	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.263.json	Indication for Olanzapine	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.264.json	Prednisone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.265.json	As Needed PRN	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.3.266.json	Amivantamab Injectable	active	2025-04	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.200.json	Doxorubicin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.201.json	Epirubicin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.202.json	Capecitabine	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.203.json	Cyclophosphamide	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.204.json	Injectable Fluorouracil	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.205.json	Methotrexate	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.206.json	Trastuzumab and Biosimilars	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.207.json	HER2 Presence in Tissue	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.208.json	Carboplatin	active	2020-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.209.json	Depression Screening for Adult	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.210.json	Long Acting Opioids	active	2020-10	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.211.json	High Fiber Supplement or Diet Education	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.212.json	Dexamethasone	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.213.json	Olanzapine	active	2021-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.214.json	Pancreatic Cancer	active	2020-10	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.215.json	Audio Visual Telehealth Encounter	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.216.json	Telephone Encounter	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.217.json	Telehealth Emergency Department or Initial Inpatient	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.218.json	Dyspnea Assessment	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.219.json	Nausea or Vomiting Assessment	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.220.json	Karnofsky Performance Status	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.221.json	Referral to Hospice Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.222.json	Referral to Palliative Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.223.json	Palliative Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.224.json	Enrollment in Hospice Care	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.225.json	Advance Directive Including Durable Power of Attorney or Instructional	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.229.json	Minimal Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.232.json	Epithelial Ovarian Cancer	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.233.json	Primary Peritoneal Cancer	active	2022-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.235.json	BRCA2 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.236.json	Multigene Panel	active	2023-07	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.237.json	BRCA1 Testing	active	2023-06	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.238.json	First Line Drug Therapy for Metastatic Colorectal Cancer	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.239.json	BRAF V600 Testing	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.240.json	Cancer Stage 4	active	2022-01	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.241.json	Cancer Stage M1	active	2024-12	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.242.json	High Emetic Risk Intravenous Antineoplastic Agent	active	2022-09	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.243.json	Moderate Emetic Risk Intravenous Antineoplastic Agent	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.245.json	Antiemetic Agent	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.247.json	Indication for Dexamethasone	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.1444.5.249.json	Indication for Olanzapine	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.2074.1.1.3.json	Race Category Excluding Nulls	active	2024-06	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.1002.77.json	Codeine	active	2024-02	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.1004.13.json	Dihydrocodeine	active	2024-02	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.1004.14.json	Nalbuphine	active	2020-03	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4009.json	Malignant Intracranial Neoplasm	active	2024-02	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4010.json	Malignant Intracranial Neoplasm	active	2023-02	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4015.json	STEMI	active	2022-02	us	hl7	2
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4016.json	STEMI	active	2019-02	us	hl7	1
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4017.json	STEMI	active	2022-03	us	hl7
us.nlm.vsac	R4	ValueSet/ValueSet-2.16.840.1.113883.3.3157.4019.json	Fibrinolytic Therapy	active	2023-02	us	hl7